Inhibiting the formation of classical C3-convertase on the Alzheimer's β-amyloid peptide

Immunopharmacology

Volumn 38, Issue 1-2, 1997, Pages 101-109

  Emmerling, Mark R ^a   Spiegel, Katharyn ^a   Watson, M Desiree ^a  

^a PFIZER INC   (United States)

Author keywords

Amyloid peptide; Alzheimer's disease; C3a; Inflammation; Neurodegeneration

Indexed keywords

AMYLOID BETA PROTEIN; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE;

ALZHEIMER DISEASE; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; ENZYME ACTIVATION; HIPPOCAMPUS; HUMAN; INFLAMMATION; NEOCORTEX; NERVE DEGENERATION; PRIORITY JOURNAL;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BRAIN; CHELATING AGENTS; COLORING AGENTS; COMPLEMENT ACTIVATION; COMPLEMENT C1 INACTIVATOR PROTEINS; COMPLEMENT C1Q; COMPLEMENT C3-C5 CONVERTASES; COMPLEMENT C3A; COMPLEMENT C4; CONGO RED; EGTAZIC ACID; HUMANS; NERVE DEGENERATION; PROTEASE INHIBITORS;

EID: 0031444893     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(97)00067-2     Document Type: Article

References (51)

1. Afagh, A., Cummings, B.J., Cribbs, D.H., Cotman, C.W., Tenner, A.J., 1996. Localization and cell association of Clq in Alzheimer's disease brain. Exp. Neurol. 138, 22-32.
2. Aoyama, T., Ino, Y., Ozeki, M., Oda, M., Sato, T., Koshiyama, Y., Suzuki, S., Fujita, M., 1984. Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments. Jpn. J. Pharmacol., 203-227.
3. Barnum, S.R., 1995. Complement biosynthesis in the central nervous system. Crit. Rev. Oral Biol. Med. 6, 132-146.
4. Bean, A.J., Xu, Z., Chai, S.Y., Brimijoin, S., Hokfelt, T., 1991. Effect of intracerebral injection of monoclonal acetylcholinesterase antibodies on cholinergic nerve terminals in the rat central nervous system. Neurosci. Lett. 133, 145-149.
5. Brachova, L., Lue, L.F., Schultz, J., el Rashidy, T., Rogers, J., 1993. Association cortex, cerebellum, and serum concentrations of Clq and factor B in Alzheimer's disease. Mol. Brain Res. 18, 329-334.
6. Bradt, B.M., Bixby, T.S., Kolb, W.P., Cooper, N.R., 1996a. Covalent binding of Alzheimer's disease A β peptide with C3 via activation of both complement pathways. Mol. Immunol. 33, 27.
7. Bradt, B.M., Bixby, T.S., Cooper, N.R., 1996b. The Alzheimer's Disease A β peptide generates C5a and sC5b-9 via direct activation of both complement pathways. Mol. Immunology 33, 27.
8. Brimijoin. S., Moser, V., Hammond, P., Oka, N., Lennon, V.A., 1993. Death of intermediolateral spinal cord neurons follows selective, complement-mediated destruction of peripheral preganglionic sympathetic terminals by acetylcholinesterase antibodies. Neuroscience 54, 201-223.
9. Cooper, N.R., 1975. Enzymatic activity of the second component of complement. Biochem. 14, 4245-4251.
10. Dagerlind, A., Pelto Huikko, M., Lundberg, J.M., Ubink, R., Verhofstad, A., Brimijoin, S., Hokfelt, T., 1994. Immunologically induced sympathectomy of preganglionic nerves by antibodies against acetylcholinesterase: increased levels of peptides and their messenger RNAs in rat adrenal chromaffin cells. Neuroscience 62, 217-239.
11. Eikelenboom, P., Rozemuller, J.M., Kraal, G., Stam, F.C., McBride, P.A., Bruce, M.E., Fraser, H., 1991. Cerebral amyloid plaques in Alzheimer's disease but not in scrapie-affected mice are closely associated with a local inflammatory process. Virchows Arch B Cell. Pathol. Incl. Mol. Pathol. 60, 329-336.
12. Eikelenboom, P., Veerhuis, R., 1996. The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiol. of Aging 17, 673-680.
13. Fraser, P.E., Nguyen, J.T., Chin, D.T., Kirschner, D.A., 1992. Effects of sulfate ions on Alzheimer β/A4 peptide assemblies: implications for amyloid fibril-proteoglycan interactions. J. Neurochem. 59, 1531-1540.
14. Fukumoto, H., Asami Odaka, A., Suzuki, N., Iwatsubo, T., 1996. Association of A β 40-positive senile plaques with microglial cells in the brains of patients with Alzheimer's disease and in non-demented aged individuals. Neurodegeneration 5, 13-17.
15. Gasque, P., Fontaine, M., Morgan, B.P., 1995a. Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J. Immunol. 154, 4726-4733.
16. Gasque, P., Chan, P., Fontaine, M., Ischenko, A., Lamacz, M., Gotze, O., Morgan, B.P., 1995b. Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes. J. Immunol. 155, 4882-4889.
17. Gasque, P., Singhrao, S.K., Neal. J.W., Moretto, G., Morgan, B.P., 1997. The anaphylatoxin C3a receptor (C3aR) expressed by neurons and glial cells in vitro is found in normal and inflamed brain. Exp. Clin. Immunogenet. 14, 83.
18. Graeber, M.B., Streit, W.J., Kreutzberg, G.W., 1988. Axotomy of the rat facial nerve leads to increased CR3 complement receptor expression by activated microglial cells. J. Neurosci. Res. 21, 18-24.
19. Gowing, E., Roher, A.E., Woods, A.S., Cotter, R.J., Chaney, M., Little, S.P., Ball, M.J., 1994. Chemical characterization of A β 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. J. Biol. Chem. 269, 10987-10990.
20. Ischenko, A.M., Sayah, S., Zhakhova, A.V., Gamaley, I.A., Klyubin, I.V., Kirpichnikova, K.M., Patte, C., Vaudry, H., Fontaine, M., 1997. Astrocytic cell responses to complement anaphylatoxins and their peptide analogs. Exp. Clin. Immunogenet. 14, 84.
21. Ishii, T., Haga, S., 1984. Immuno-electron microscopic localization of complement in the amyloid fibrils of senile plaques. Acta Neuropathol. 63, 296-300.
22. Joachim, C.L., Selkoe, D.J., 1992. The seminal role of β-amyloid in the pathogenesis of Alzheimer Disease. Alzheimer Dis. Assoc. Disorders 6, 7-34.
23. Jiang, H., Burdick, D., Glabe, C.G., Cotman, C.W., Tenner, A.J., 1994. β-Amyloid activates complement by binding to a specific region of the collagen-like domain of the Clq A chain. J. Immunol. 152, 5050-5059.
24. Lacy, M., Whittemore, S.R., Haviland, D.L., Wetsel, R.A., Barnum, S.R., 1995. Expression of the receptors for the C5a anaphylatoxin, interleukin-8 and fMLP by human astrocytes and microglia. J. Neuroimmunol. 61, 71-78.
25. Lalowski, M., Golabek, A., Lemere, C.A., Selkoe, D.J., Wisniewski, H.M., Beavis, R.C., Frangione, B., Wisniewski, T., 1996. The 'nonamyloidogenic' p3 fragment (amyloid β17-42) is a major constituent of Down's Syndrome cerebellar preamyloid. J. Biol.Chem. 271, 33623-33631.
26. Law, S.K., Lichtenberg, N.A., Levine, R.P., 1980. Covalent binding and hemolytic activity of complement proteins. Proc. Natl. Acad. Sci. 77, 7194-7198.
27. LeVine, H., 1995. Thioflavine T interaction with amyloid β-sheet structures. Amyloid 2, 1-6.
28. Lorenzo, A., Yankner, B.A., 1994. β-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. 91, 12243-12247.
29. Lue, L.-F., Rogers, J., 1992. Full complement activation fails in diffuse plaques of the Alzheimer's disease cerebellum. Dementia 3, 308-313.
30. Lue, L.-F., Brachova, L., Civin, W.H., Rogers, J., 1996. Inflammation, A β deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. J. Neuropathol. Exp. Neurol. 55, 1083-1088.
31. Mann, D.M., Iwatsubo, T., Fukumoto, H., Ihara, Y., Odaka, A., Suzuki, N., 1995. Microglial cells and amyloid beta protein (A β) deposition; association with Aβ 40-containing plaques. Acta Neuropathol. 90, 472-477.
32. McGeer, P.L., McGeer, E.G., Kawamata, T., Yamada, T., Akiyama, H., 1991. Reactions of the immune system in chronic degenerative neurological diseases. Can. J. Neurol. Sci. 18, 376-379.
33. McPhaden, A.R., Whaley, K., 1992. The Complement System and Inflammation. In: Biochemistry of Inflamation. Whicher, J.T. and Evans, S.W. (Eds.), Kluwer Academic Publishers, Boston, MA, pp. 17-36.
34. i signaling in mouse microglia. J. Neuroscience 17, 615-624.
35. Morgan, B.P., 1989. Complement membrane attack on nucleated cells: Resisitance, recovery, and non-lethal effects. Biochem. J. 264, 1-14.
36. Piddlesden, S.J., Storch, M.K., Hibbs, M., Freeman, A.M., Lassmann, H., Morgan. B.P., 1994. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J. Immunol. 152, 5477-5484.
37. Piddlesden, S.J., Jiang, S., Vincent, A., Morgan, B.P., 1996. Soluble complement receptor 1 (SCR1; TP10) protects against experimental allergic myasthenia gravis (EAMG). Mol. Immunol. 33, 76.
38. Pollack, S.J., Sadler II, Hawtin, S.R., Tailor, V.J., Shearman, M.S., 1995. Sulfonated dyes attenuate the toxic effects of β-amyloid in a structure-specific fashion. Neurosci. Lett. 197, 211-214.
39. Rogers, J., Cooper, N.R., Webster, S., Schultz, J., McGeer, P.L., Styren, S.D., Civin, W.H., Brachova, L., Bradt, B., Ward, P., Lieberburg, I., 1992. Complement activation by β-amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. 89, 10016-10020.
40. Rogers, J., Websler, S., Lih-Fen, L., Brachova, L., Civin, W.H., Emmerling, M., Shivers, B., Walker, D., McGeer, P., 1996. Inflammation and Alzheimer's Disease Pathogenesis. Neurobiol. Aging 17, 681-686.
41. Rozemuller, J.M., Stam, F.C., Eikelenboom, P., 1990. Acute phase proteins are present in amorphous plaques in the cerebral but not in the cerebellar cortex of patients with Alzheimer's disease. Neurosci. Lett. 119, 75-78.
42. Sadler II, Smith, D.W., Shearman, M.S., Ragan, C.I., Tailor, V.J., Pollack, S.J., 1995. Sulphated compounds attenuate betaamyloid toxicity by inhibiting its association with cells. Neuroreport 7, 49-53.
43. Snow, A.D., Kinsella, M.G., Parks, E., Sekiguchi, R.T., Miller, J.D., Kimata, K., Wight, T.N., 1995. Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease. Arch. Biochem. Biophys. 320, 84-95.
44. Tack, B.F., Harrison, R.A., Janatova, J., Thomas, M.L., Prahl, J.W., 1980. Evidence for presence of an internal thiolester bond in third component of human complement. Proc. Natl. Acad. Sci. 77, 5764-5768.
45. Velazquez, P., Cribbs, D.H., Poulos, T.L., Tenner, A.J., 1997. Aspartate residue 7 in amyloid β-protein is critical for classical complement patheay activation: Implication for Alzheimer's disease pathogenesis. Nat. Medicine 3, 77-79.
46. Veerhuis, R., van der Valk, P., Janssen, I., Zhan, S.S., Van Nostrand, W.E., Eikelenboom, P., 1995. Complement activation in amyloid plaques in Alzheimer's disease brains does not proceed further than C3. Virchows Arch. 426, 603-610.
47. Watson, M.D., Roher, A.E., Kim, K.S., Spiegel, K., Emmerling, M.R., 1997a. Complement Labelling of Aggregated Aβ1-42 By Normal Human Serum Involves the Classical and Alternative Pathways. In: Iqbal, K., Winblad, B., Nishimura, T., Takeda, M., Wisniewski, H. (Eds.), Alzheimer's Disease: Biology, Diagnosis and Therapeutics. John Wiley and Sons, Sussex, UK, in press.
48. Watson, M.D., Roher, A.E., Kim, K.S., Spiegel, K., Emmerling, M.R., 1997b. Complement interactions with amyloid-β1-42: A nidus for inflammation in AD brains. Amyloid, in press.
49. Weisman, H.F., Bartow, T., Leppo, M.K., Marsh, H.C., Carson, G.R., Concino. M.F., Boyle, M.P., Roux, K.H., Weisfeldt, M.L., Fearon, D.T., 1990. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing postischemic myocardial inflammation and necrosis. Science 249, 146-151.
50. Wood, S.J., MacKenzie, L., Maleeff, B., Hurle, M.R., Wetzel, R., 1996. Selective inhibition of Aβ fibril formation. J. Biol. Chem. 271, 4086-4092.
51. Yao, J., Harvath, L., Gilbert, D.L., Colton, C.A., 1990. Chemotaxis by a CNS macrophage, the microglia. J. Neurosci. Res. 27, 30-42.